Reference
1. Gido, R.D.S., A.L. Wojciechowski, and R.P. Bajwa, Pulmonary infection with Mycobacterium szulgai: A case report. SAGE open medical case reports, 2019. 7 : p. 2050313X18823448.
2. Martín-Casabona, N., et al., Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. The International Journal of Tuberculosis and Lung Disease, 2004.8 (10): p. 1186-1193.
3. Marks, J., P. Jenkins, and M. Tsukamura, Mycobacterium szulgai—a new pathogen. Tubercle, 1972. 53 (3): p. 210-214.
4. Khan, S., et al., Pulmonary Mycobacterium szulgai infection: a case report. QJM: An International Journal of Medicine, 2016.109 (7): p. 489-490.
5. Sánchez-Alarcos, J.M., et al., Pulmonary infection due to Mycobacterium szulgai. Respiration, 2003. 70 (5): p. 533-536.
6. Griffith, D.E., et al., An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American journal of respiratory and critical care medicine, 2007. 175 (4): p. 367-416.
7. Lio, J., Y. Lee, and R. Obata, Comparison of Characteristics of Fibrocavitary and Bronchiectasis Phenotypes of Pulmonary Mycobacterium Avium , in A106. NTM: BENCH TO BEDSIDE . 2019, American Thoracic Society. p. A2524-A2524.
8. Lake, M.A., et al., ‘” Why me, why now?” Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. BMC medicine, 2016. 14 (1): p. 54.
9. Erickson, K.L., E.A. Medina, and N.E. Hubbard, Micronutrients and innate immunity. The Journal of infectious diseases, 2000.182 (Supplement_1): p. S5-S10.
10. Fischer, J., et al., Analogue-based drug discovery . 2010: Wiley-VCH Hoboken, NJ.
11. Basille, D., V. Jounieaux, and C. Andréjak. Treatment of other nontuberculous mycobacteria . in Seminars in respiratory and critical care medicine . 2018. Thieme Medical Publishers.